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KESAN MORINDA CITRIFOLIA (LINN.) TERHADAP METABOLISME  
DRUG FASA I DAN II DAN PENCIRIAN MEKANISME MOLEKUL  
DALAM HATI TIKUS 
  
ABSTRAK  
 
 
Morinda citrofilia umumnya dikenali sebagai Noni dan orang tempatan menamakannya 
mengkudu adalah satu di antara tumbuhan ubat Polinesia yang sangat penting. 
Morinda citifolia (Noni) telah digunakan secara meluas dalam perubatan kampong oleh 
orang-orang Polinesia sejak lebih 2000 tahun dahulu. Ia dikatakan mempunyai kesan 
terapeutik yang meluas termasuk kegunaan antikanser dalam klinikal, dan terhadap 
haiwan makmal, dan juga bekesan sebagai agen antibakteria, antivirus, antikulat, 
antihelmin, analgesik, antihipotensif, antiinflamasi dan juga mempunyai kesan 
menguatkan sistem imun. Penggunaan ubat herba bersama dengan ubat-ubatan 
moden sekarang ini menjadi semakin popular, kemungkinan interaksi (saling tindakan) 
diantara herba dan drug bertambah. Hanya sedikit diketahui tentang kejadian dan 
akibat interaksi herba-drug dalam pesakit yang menerima produk herba jus mengkudu. 
Tujuan penyelidikan ini  adalah menjalankan kajian pendahuluan in-vitro kesan  
M. citrofilia terhadap enzim metabolisme fasa I dan fasa II dalam hati tikus; pengaruh 
penyakit (diabetes dan hipertensi), jantina dan umur terhadap kesan M. citrifolia dan 
juga untuk pencirian mekanisme peringkat molekul  kesan M. citrifolia keatas 
metabolisme aminopirin fasa I.  
 
Kajian in-vitro kami menunjukkan ekstrak jus mengkudu (MJE), Hawaiian Noni 
juice (HNJ) dan Tahiti Noni juice (TNJ) telah meningkatkan metabolisme aminopirin 
terutamanya pada kepekatan tinggi dalam tikus normal (NR), tikus diabetik (DR) dan 
tikut hipertensif spontan (SHR). Kajian ini telah menunjukkan penyakit diabetes dan 
perbezaan jantina mempengaruhi secara signifikan kesan in-vitro M.  citrofilia ke atas 
metabolisme aminopirin. Dalam kajian akut (satu hari) pemberian secara oral MJE, 
aktiviti aminopirin N-demetilase meningkat secara signifikan pada semua paras dos 
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yang tinggi (210mg/kg), sementara aktiviti glutation S-transferase (GST) naik secara 
signifikan pada kepekatan 2.1, 21, 210 mg/kg. Walaubagaimana pun, kajian sub-
kronik, aktiviti uridin difosfat-glukuronosil transferase (UDP-GT) turun secara signifikan 
tetapi bergantung kepada dos sementara aktiviti aminopirin N-demetilase juga turun 
walaupun tidak signifikan.  
 
Kemungkinan adanya interaksi yang serupa terjadi in-vitro dan ex-vivo dengan 
drug-drug lain yang mengalami konjugasi N-demetilase hepatik fasa I dan/atau fasa II. 
Kemungkinan kesan yang serupa terhasil secara in-vivo perlu ada kajian seterusnya.  
Kajian mekanisme molekul mencadangkan protein kinase A mungkin terlibat dalam 
mekanisme peringkat molekul bagi kesan akut MJE keatas metabolisme aminopirin 
dalam tikus muda betina SHR. Penskrinan kualitatif menggunakan spektroskopi IR, 
1HNMR dan HPTLC menunjukkan sampel-sampel  M. citrifolia yang diuji mempunyai 
persamaan secara kualitatif dalam kandungan utamanya. Ciri-ciri kandungan ini 
kebanyakannya menyerupai kumpulan-kumpulan fungsi sebatian antrakuinon, sterol, 
glikosida dan flavonol yang telah dilaporkan oleh beberapa pengkaji sebelum ini. 
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EFFECT OF MORINDA CITRIFOLIA (LINN.) ON PHASE I AND II DRUG 
METABOLISM AND ITS MOLECULAR MECHANISM ELUCIDATION            
IN RAT LIVER 
 
ABSTRACT  
 
Morinda citrifolia commonly known as Noni and locally known as mengkudu is one of 
the most important traditional Polynesian medicinal plants. Morinda citrifolia (Noni) has 
been used extensively in folk medicine by Polynesians for over 2,000 years. It has 
been reported to have broad therapeutic effects, including anticancer properties in 
clinical practice and in laboratory animal models and are effective as antibacterial, 
antiviral, antifungal, antihelminthics, analgesic, hypotensive, anti-inflammatory agents, 
and immune system enhancing effects. As the use of phytomedicine together with 
modern medications has become more popular nowadays, the possibilities of herb-
drug interactions have increased. Little is known about the incidence and 
consequences of herb-drug interactions in patients receiving herbal product of 
mengkudu juice. The aims of the study were to investigate, primarily, the in-vitro effect 
of Morinda citrifolia on phase I and II metabolizing enzymes in rat liver; the influence of 
diseases (diabetes and hypertension), gender and age on the foregoing effect, as well 
as to elucidate the molecular mechanism of M. citrifolia effect on aminopyrine phase I 
metabolism.  
 
Our in-vitro study showed that effect of mengkudu juice extract (MJE), Hawaiian 
Noni juice (HNJ) and Tahiti Noni juice (TNJ) of M. citrifolia increased aminopyrine 
metabolism especially at high concentrations in normal rat (NR), diabetic rat (DR) and 
spontaneously hypertensive rats (SHR). This study shows that, diabetes and gender 
differences have significantly influenced the in-vitro effects of M. citrifolia on liver 
aminopyrine metabolism. In acute study (one day) of orally administrated MJE, the 
aminopyrine N-demethylase activity was significantly increased at the highest dose 
level (210 mg/kg) while the activity of glutathione S-transferase (GST) was significantly 
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increased at 2.1, 21 and 210 mg/kg concentrations. However, in the sub-chronic study, 
uridine diphosphate glucuronosyltransferase (UDP-GT) activity was significantly 
decreased but was dose independent while aminopyrine N-demethylase activity was 
not changed.  
 
A possibility exist that similar interactions may occur in-vitro and ex-vivo with 
other drugs that undergo the same hepatic phase I N-demethylation and/or hepatic 
phase II conjugations. Whether this effect is similarly produced in-vivo still needs 
further investigation. The molecular mechanism study suggests that protein kinase A 
may be involved in the molecular mechanism of MJE acute effect on aminopyrine 
metabolism in young female SHR. Qualitative screening using IR, 1HNMR 
spectroscopies and HPTLC showed that the tested samples of M. citrifolia have 
qualitative similarities in their major constituents. The characteristics of these 
constituents mostly resemble the functional groups of anthraquinones, sterols, 
glycoside and flavonol compounds which have been reported by several authors. 
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CHAPTER ONE   
GENERAL INTRODUCTION  
 
1.1      History of Herbal Drugs    
The WHO (2000) has defined herbs to include crude plant materials such as 
leaves, flowers, fruits, seeds, stems, wood, barks, root, rhizomes or other plant parts 
which may be complete, fragmented or powdered. On the other hand, herbal products 
consist of herbal preparations made from one or more herbs. It may contain excipients 
in addition to the active ingredients. In their unprocessed state, these herbal drugs are 
usually in the dried form but are sometimes stored fresh. Certain exudates may also be 
considered as herbal drugs. Herbal medicine is defined as the use of crude drugs of 
plant origin to treat illness or to promote health. Phytomedicinals including capsules, 
tablets, tinctures, and fluid extracts are those common preparations that have been 
prepared from plant sources.  
 
Phytomedicine, the use of plants or their parts to treat ailments has been part of 
humankind’s attempt to free itself of disease for several thousand years. Some of the 
earliest writings found on Babylonian clay tablets from 3000 B.C. are about plants used 
for ceremonial, magical, and medicinal purposes. During the next thousand years, 
parallel cultures in China, India, and Egypt developed written records of medicinal 
herbs. Among these early historical documentations, the ancient Middle Easterners 
appear to have been the one of the first to rigorously document the use of plants for the 
treatment of various diseases, compiling these information in the first known 
pharmacopoeia entitled Materia Medica. The Greek historian Herodotus recounts how 
the Egyptians worshiped certain plants (Fetrow & O'Neil, 2002).  
 
As science emerged after the 17th century, herbal plants were classified and 
demystified. Extraction of the relevant chemicals from these plants became popular 
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around the turn of the 19th century. As science advanced, medicines were synthesized 
and herbalism declined. Newly developed principles of organic chemistry made it 
possible to replicate plant-produced chemicals leading to the synthesis of new 
compounds that preserved the beneficial properties of the natural chemical, but 
minimized its toxic effects (Fetrow & O'Neil, 2002).  
 
Many medicines that we use today were isolated from plants sources. Research 
reveals that approximately 25-33% of currently available modern medicines in the 
United States have their origins in plants, animal, or mineral systems. The focus on 
synthesized and biotechnologically derived medicines has continued to this day. 
However, in the latter part of the 20th century, there has been an intense renewed 
interest in herbalism (Fetrow & O'Neil, 2002).   
 
New medicines have been discovered with traditional, empirical and molecular       
approaches (Harvey, 1999). The traditional approach makes use of materials that has 
been discovered via trial and error modes over many years in different cultures and 
systems of medicine (Cotton, 1996). Examples include drugs such as morphine, 
quinine and ephedrine that have been in widespread use for a long time, and more 
recently adopted compounds such as the antimalarial artemisinin. The empirical 
approach builds on an understanding of a relevant physiological process and often 
develops a therapeutic agent from a naturally occurring lead molecule (Verpoorte, 
1989; Verpoorte 2000). Examples include tubocurarine and other muscle relaxants, 
propranolol and other β-adrenoceptor antagonists, and cimetidine and other 
histamine H2 receptor antagonists. The molecular approach is based on the availability 
or understanding of a molecular target for the medicinal agent (Harvey, 1999). With the 
development of molecular biological techniques and advances in genomics, the 
majority of drug discovery is currently based on the molecular approach.  
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The major advantage of natural products for random screening is the structural 
diversity provided by these products, which is greater than that provided by most 
available combinatorial approaches based on heterocyclic compounds (Claeson & 
Bohlin, 1997; Harvey, 1999). Bioactive natural products often occur as a part of a 
family of related molecules. Thus, it is possible to isolate a number of homologues and 
obtain structure-activity information. Lead compounds discovered through the 
screening of natural products can of course be optimized by traditional medicinal 
chemistry or by the application of combinatorial approaches. Overall, when faced with 
molecular targets in screening assays for which there is no information about low 
molecular weight leads, the use of a natural products library seems more likely to 
provide the chemical diversity to yield success rather than the use of a library of similar 
numbers of compounds made by combinatorial synthesis. Since only a small fraction of 
the world’s biodiversity has been tested for biological activity, it can be assumed that 
natural products will continue to offer novel leads for novel therapeutic agents, if these 
natural products are available for screening.   
 
At present, more than 80,000 secondary metabolites have been identified in 
higher plant species (Loyola-Vargas & Miranda-Ham, 1995). 75-80 % of the world’s 
population relies on these plant-based medicines and one in four of commercial 
pharmaceutical products are derived from plant-based sources (Pal & Shukla, 2003). 
Secondary metabolites are bioactive molecules which provide the plant with defense 
mechanisms to survive herbivores, environmental stress, disease or competition and 
may effect the growth and development of other organisms (Seigler, 1996). Each 
individual species has a unique profile of secondary metabolites and it is this pool of 
biochemicals that commonly contains the medicinally active components (Murch et al., 
2001).  
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1.2 Natural Products and Biodiversity  
 Natural products produced by plants, fungi, bacteria, insects and animals have 
been isolated as biologically active pharmacophores. Natural products have the 
potential to provide medicine through a source of novel structures that are unobtainable 
from other sources such as combinatorial synthesis. This is because nature is capable 
of producing complex molecules with multiple chiral centers that are designed to 
interact with biological systems (Cordell, 2000). Because biodiversity is so important to 
the continued discovery of novel natural products, it is important to know how much of 
this biodiversity remains. The greater the amount of remaining biodiversity to be 
studied, the greater the potential amount of chemical diversity that remains to be 
discovered. It has been estimated that of the approximately 250,000 plant species only, 
about 5-15% of them have been investigated for bioactive compounds (Kong et al., 
2003). Based on the above information, it is obvious that there is still an abundance of 
plant species available for investigation.  
 
Cancer is the second leading cause of death in the United States; one out of 
every four deaths is from cancer. During 2002, it was estimated that over 1.28 million 
people will die of cancer (this figure does not include noninvasive cancers). The death 
rate for patients with cancer is 38%. The National Institutes of Health (NIH) has 
estimated the cost for cancer treatment to be US$ 156.7 billion. It is also important to 
note that 77% of all cancers diagnosed are in people 55 years of age or older 
(American Cancer Society, 2003). With cancer taking such a toll on the population, 
both in terms of lives and cost, the discovery of anticancer drugs has become very 
important. When one considers the aging population of the United States, it is clear that 
these numbers are likely to increase in the years to come, and the search for more 
effective drugs will become even more important. Some of the most effective cancer 
treatments to date involve the use of natural products or compounds derived from 
natural products. Numerous epidemiological studies have shown that diets low in fat 
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and rich in complex carbohydrates derived from vegetables, fruits and grains are 
associated with decreased risk of chronic diseases (Dragsted et al., 1993). For 
example, grapefruit juice inhibits CYP3A4, (Bourian et al., 1999) and vegetables such 
as brussel sprouts and broccoli whose glucosilinate compounds induce CYP1A2 
(Fontana et al., 1999). These enzymes metabolize many carcinogens, including 
tobacco related compounds and char grilled meat. In fact, induction of 1A2 underlies 
the cancer preventative reputation of family Brassicaceae.  
 
Natural phenolic compounds make a considerable contribution to the nutritional 
quality of fruits and fruit products, which play an important role in the daily diet. They 
also play a key role in antioxidative defence mechanisms in biological systems and 
they may have an inhibitory effect on mutagenesis and carcinogenesis. Attention has 
turned to plant phenols because the use of synthetic antioxidants has been declining 
due to their suspected action as cancer promoters (Ho, 1992a). Caffeic acid, gallic acid 
and gallic acid derivatives (methyl-, lauryl- and propylgallates) show strong antioxidant 
properties and act as free radical acceptors (Ho, 1992b). They are widely used as food 
additives to protect lipid structures. Nevertheless, phenols can simultaneously have 
pro-oxidant effects, i.e. cause tissue damage by producing reactive oxygen species 
(ROS), and their consumption should be couched with caution (Aruoma et al., 1993). 
The important biological activities of simple benzenoids, e.g. chlorogenic, caffeic, 
ferulic, gallic and ellagic acids, are probably due to their cytoprotective activity and 
possible inhibitory effects on carcinogenesis, mutagenesis and tumorigenesis (Lesca, 
1983; Stich & Rosin, 1984; Chang et al., 1985; Mukhtar et al., 1988; Vieira et al., 1998; 
Haslam, 1998; Kumar & Muller,1999). Flavonoids have a range of in-vitro as well as in-
vivo biological effects on a great number of mammalian cell systems. Flavonoids have 
been shown to possess antiviral and endocrine effects, effects on mammalian 
enzymes, effects on the modulation of immune and inflammatory cell functions, effects 
on smooth muscles, and effects on lipid peroxidation and oxyradical production 
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(Harborne, 1994; Formica & Regelson, 1995). Since flavonoids are regular constituents 
of our every day diet, their possible genotoxic, carcinogenicity, and mutagenicity 
related properties have recently received increasing attention (Manson & Benford, 
1999). Although evidence from human and animal, as well as in-vitro experiments, 
support the hypothesis that flavonoids promote health, it is possible that interactions 
with other dietary constituents or lifestyles may override any subtle positive effects of 
flavonoids in humans (Moskaug et al., 2004).   
 
1.3 Background of Herbal Medicine in Malaysia  
Malaysia is rich in natural resources basic to herbal medicine. There are over 
6000 species of tropical plants all over the country and in Peninsula Malaysia there are 
550 genera containing 1300 species (Zakaria & Mohd, 1994). Past and present 
ethanobotanical or ethanomedical surveys suggest that at least about 20% of the 
estimated total of higher plant flora of 15,000 species comprise of plants which have 
been reported to possess medicinal and other therapeutic properties (Soepadmo, 
1993).  
 
 Malaysia, as a multiracial country, markets four major groups of herbal 
medicine namely Malay herbal medicine, Indian herbal medicine, Chinese herbal 
medicine and Western herbal medicine. Every racial group has its own method or way 
of curing diseases and depends very much on the practice, belief and knowledge each 
one possesses. This search for cures to various diseases through the use of herbalism 
has indirectly fostered inter-racial interactions (Zakaria & Mohd, 1994).  
 
 Malay herbal medicine has been influenced by various foreign medicinal 
elements. The local Malay herbal medicine framework is actually based on old 
Indonesian herbal medicine approaches, which have been modified to suit local and 
current needs. Chinese and Indian immigrants brought with them various medicinal 
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plants which grew well in this country. The popularity of Chinese herbal medicine is 
evident from the presence of about 1000 medicinal shops commonly known as ‘kedai 
sinseh’ (Zakaria & Mohd, 1994).   
 
However, the major problems faced by herbal medicine practitioners of all the 
four groups are firstly, the lack of clinical data to substantiate efficacy claims and 
secondly, non-existence of standards for most herbal materials and products.  
 
Increasingly, alternative therapies such as herbal products are being used in 
the world. For example in the United States approximately 25% of American who 
consult their physician about a serious health problem are employing  unconventional 
therapy, but only 70% of these patient inform their physician of such use (Eisenberg et 
al., 1993). Most people believe that the herbal medicines have no side effects or any 
potential risk due to its natural origins and as such herbs are often administered in 
combination with therapeutic drugs. The manufacturers of these products are not 
required to submit proof of safety and efficacy before marketing because herbs are 
considered as food supplements and not drugs. Due to the foregoing reasons, the use 
of herbs in medical therapy increases the potential of pharmacokinetic and/or 
pharmacodynamic herb-drug interaction. Here, emphasis is placed primarily on the 
pharmacokinetic aspects, partly because pharmacokinetic interaction is the most 
common cause of undesirable and to date unpredictable effects (Ito et al., 1998). 
Moreover, my study is devoted to this aspect especially to one major component 
namely drug metabolism.   
 
1.4  Drug Interactions  
The particular response to a drug is determined in one way or another by the 
concentration of the drug, and some time its metabolite at the effect sites within the 
body. Accordingly, it is useful to divide the relationship between drug administration 
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and response into two phases, a pharmacokinetic phase, which refers to drug 
administration and its concentration within the body over time, and a pharmacodynamic 
phase, which refers to the responses (desired and undesired) produced in reaction to 
drug concentrations.  
 
Pharmacokinetic processes in-vivo can be broadly divided into two parts, 
absorption which is usually defined as the passage of a drug from its site of 
administration into the circulatory system (Schanker, 1971); and its disposition, which 
applies to all sites of drug administration other than its direct injection into the blood 
stream and comprises all processes between a drug’s administration to its appearance 
in the blood circulatory system. Bioavailability is a measure of the extent of drug 
absorption. Disposition comprises both the distribution of drugs into tissues within the 
body and their elimination and is itself divided into metabolism and excretion in 
unchanged form. The kidney and the liver are the main organs in the body for drug 
elimination; the kidney excretes drugs through urine unchanged and/or after 
metabolism by the liver while the liver can excrete a drug through the bile duct after 
metabolism. For many drugs, metabolism occurs in two distinct phases. Phase I 
involves the formation of a new or modified functional group or a cleavage. Phase II 
involves conjugation within an endogenous compound.  
 
1.4.1 Pharmacokinetic Drug Interactions 
 Simply, drug interaction can be defined as a change in a drug’s effect when 
administered with another drug, herb, or food. For example, two or more drugs, taken 
together can change the way a drug works in the body. This possibly could make one 
or more of these drugs less safe or reduce their efficacy. There are two main types of 
drug interactions: pharmacodynamic and pharmacokinetic drug interactions. 
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Pharmacokinetic interaction may occur during absorption and/or transportation 
whence the metabolism of the drugs alters physiological function. A transporter 
interaction occurs within organs such as the brain, to produce altered drug distribution, 
not excretion. This occurs, for example, with inhibition of the efflux transporter             
P-glycoprotein (PGP) located within the blood brain barrier (BBB). This inhibition of 
PGP leads to an elevation in cyclosporine levels in the brain (Tanaka et al., 2000). 
Absorption interaction involves a change in either the rate or the extent of drug 
absorption, particularly following oral administration. There are many potential sites for 
absorption interaction within the gastric and intestinal lumen, at or within the gut wall, 
as well as within the liver. When an absorption interaction leads to a reduction in 
absorption, kinetics will result in lower and altered peak concentrations, which could be 
critical if the drug is intended for rapid onset of action, such as for the relief of a 
headache. Metabolism interaction occurs in the induction or inhibition of phase I and/or 
phase II enzymes and the depletion of substrates used by phase II enzymes. Over the 
last 10-15 years, metabolism interaction has been the major focus for drug interactions.   
 
1.5 Drug Metabolism and Metabolism-Based Drug Interactions 
The liver is rightfully considered to be the most important organ involved in drug 
metabolism. Drug bioavailability is controlled by the liver’s capacity to clear the drug 
from circulation. This depends on both blood flow and the efficiency of drug removal by 
hepatocytes (extraction ratio). Drug metabolism involves a wide range of chemical 
reactions, including oxidation, reduction, hydrolysis, hydration, conjugation, 
condensation, and isomerization. The enzymes involved are present in many tissues 
but generally are more concentrated in the liver.  For many drugs, metabolism occurs 
in two apparent phases. Phase I reactions involve the formation of a new or modified 
functional group or a cleavage (oxidation, reduction and hydrolysis); these are known 
as non-synthetic reactions. Phase II reactions involve conjugation with an endogenous 
compound (eg, glucuronic acid, sulfate, and glycine) and are therefore known as 
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synthetic reactions. Metabolites formed in synthetic reactions are more polar and more 
readily excreted by the kidneys (in urine) and/or the liver (in bile) than those formed in 
non-synthetic reactions. Some drugs undergo either phase I or phase II reactions; thus, 
phase numbers reflect functional rather than sequential classification. Phase I oxidation 
occurs primarily via the hepatic mono-oxygenase (mixed function oxidase) system, a 
complex enzyme system centered on the heme protein cytochrome P-450. This system 
is under genetic control and is highly sensitive to induction (stimulation) or inhibition by 
many factors (e.g. drugs, insecticides, herbicides, smoking, caffeine). Thus, hepatic 
drug metabolism varies widely among individuals.   
 
1.6 Herbal-drug Interactions  
Xenobiotics, drugs, and a variety of naturally occurring dietary or herbal 
constituents can interact in several ways with the CYP450 system as outlined below:  
• A compound may be a substrate of, i.e. metabolized by, one or several CYP isoforms. 
If the main isoform is saturated, it becomes a substrate for the secondary enzyme(s).  
• A compound can be an inducer of a CYP isoform, either of the one it is a substrate 
for, or may induce several different enzymes at the same time. The process of 
induction increases the rate of metabolism of substrates of that enzyme.  
• A compound may also be an inhibitor of CYP450 enzymes. There are several 
mechanisms of inhibition, and a compound may inhibit several isoforms including 
others than those for which it is a substrate.  
These are then the actions that underlie the pharmacokinetic variations in drug 
metabolism, and that cause interactions between two or more drugs, or between drugs 
and nutrients, or drugs and herbs.  
 
Many herb-drug interactions have been reported. For instance, ingestion of 
broccoli may enhance CYP1A2-mediated caffeine metabolism (Kall et al., 1996). 
Echinacea (Echinacea purpurea) selectively modulates the catalytic activity of CYP3A4 
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at hepatic intestinal sites (Gorski et al., 2004). St Johns Wort interacts with drugs that 
are metabolized by cytochrome P450 isoform CYP3A4, it was suggested that St Johns 
Wort might induce CYP3A4 expression and this hypothesis was confirmed in-vivo 
(Markowitz et al., 2000) and in vitro (Moore et al., 2000).  
 
There is clear evidence of the extensive involvement of the cytochrome P450 
enzyme system in the elimination of pharmaceutical agents and there exists an 
enormous body of information demonstrating the modulation of its activity, via inhibition 
or induction, with polypharmacy. From the above, it is clear that the P450 enzyme 
system plays a main role in metabolism-based drug interactions.  
 
1.7 Review of Literature for Morinda citrifolia 
1.7.1 Botanical Aspects  
Morinda citrifolia. is a shrub which grows in sandy areas along many tropical 
coastal regions at sea level and in forest areas of up to about 1300 feet above sea 
level. Morinda citrifolia is a small evergreen tree and is identifiable by its straight trunk, 
large, bright green and elliptical leaves with tubular flowers, and its distinctive, ovoid 
"grenade-like" yellow fruit. The fruit can grow in size up to 12 cm or more and has a 
lumpy surface covered by polygonal-shaped sections. The seeds, which are triangular 
shaped, and reddish brown have an air sac attached at one end, which makes them 
buoyant. The mature fruit has a foul taste and odour. The common globally recognised 
name is Noni. Apart from this appellation, there are many local names that are also 
widely used in their respective countries namely, Nonu (Samoa), Nono (Tahiti & Cook 
Islands), Nonu (Tonga) , Noni Apple, Polynesia Fruit, Indian Mulberry (India) , Bumbo 
(Africa), Lada (Guam), Mengkudu ( Malaysia), Cheeserut (Australia), Painkiller Tree 
(Caribbean Islands), Nhau (Southeast Asia), Morinda (Vietnam), Hai Ba Ji (China), 
Kura (Fiji), Nen (Marshall Islans).  
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1.7.2 Phytochemistry  
A number of major components have been identified in the Noni plant (Morinda 
citrifolia) such as scopoletin, octanoic acid, potassium, vitamin C, terpenoids, alkaloids, 
anthraquinones (such as nordamnacanthal, morindone, rubiadin, and rubiadin-1-methyl 
ether, anthraquinone glycoside), β-sitosterol, carotene, vitamin A, flavone glycosides, 
linoleic acid, alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, 
ursolic acid, rutin, and a putative proxeronine. These constituents and their classes are 
listed in Table (1.1) and references therein.  
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    Table 1.1: The Classes of Chemical Constituents Reported in Morinda 
citrifolia (Rubiaceae) in the Literature 
     
 
 
 
 
 
 
Classes Compounds Occurrence References 
Anthraquinones Morindine, rubiadine 
Rubiadine 1-
methylether 
Roots & fruit Wang et al., 2002 
Anthraquinones Rubiadin lucidin, 
morindone, lucidin-3—
prineresal, morindone-6-
β –primeveroside,  
seven new quinones 
Cell suspension 
culture of 
M. citrifolia 
Inoue at el., 1981 
Glycosides 
 
Glycoside of coumarin,
flavone and 
anthraquinone 
Fruit Wang et al., 2000 
Essential oils 
 
Volatile oil Ripe fruit Farine et al., 1996 
Coumarone 
 
Scopoletin Fruit Farine et al., 1996 
Flavonol  
 
Vomifoliol Ripe fruit Farine et al., 1996 
Monoterpenes 
 
Iridoid Leaves Sang et al., 2003 
Sterol Campesterol 
Stigmasterol, Sitosterol  
Isofucosterol,  Sitosteryl 
palmitate, Isofucosteryl 
palmitate 
Cell suspension 
culture of        
M. citrifolia 
Dyas et al., 1994 
Vitamins Vitamin C 
24- 258 mg/100 g dried 
fruit 
Dried fruit Hirazumi & 
Furusawa, 1999 
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         Plate 1.1: Fruit of Morinda citrifolia (Rubiaceae) 
 
 
 
 
 
 
 
 
 15
1.7.3 Ethnopharmacology  
 
Morinda citrifolia is one of the traditional folk medicinal plants that has been 
used for over 2000 years in Polynesia (Wang at el., 2002). Morinda citrifolia was the 
second most popular plant used in herbal remedies to treat various common diseases 
and to maintain overall good health among Polynesians (Abbott & Shimazu, 1985). The 
Polynesians utilized the whole Noni plant in various combinations as herbal remedies. 
The fruit was eaten for health and dietary reasons (Wang at el., 2002). The fruit juice is 
in high demand as an alternative medicine for different kinds of illnesses such as 
arthritis, diabetes, high blood pressure, muscle aches and pains, menstrual difficulties, 
headaches, heart disease, AIDS, cancers, gastric ulcers, mental depression, senility, 
poor digestion, atherosclerosis, blood vessel problems, and drug addiction          
(Abbott & Shimazu, 1985). Scientific evidence on the benefits of the Noni fruit juice is 
limited but there is some anecdotal evidence for successful treatment of colds and 
influenza (Wang at el., 2002).  In Fiji, Noni was a traditional remedy used to treat 
broken bones; In India, Noni was ingested internally as a tonic during fever and was 
used as a healing application to wounds and ulcers (Singh, 1986). In Tonga, Morinda 
citrifolia (Noni) was used topically for the treatment of breast carcinomas              
(Singh at el., 1984).  This earlier chemical findings and biological activities have since 
been confirmed with more advanced techniques. Active principles or extracts of         
M. citrifolia have been shown to possess several pharmacological properties, e.g. 
analgesic, antiinflammatory, antioxidant, chemoprotective, antimicrobial, and 
immunomodulatory properties (Table 1.2).  Acubin, L-asperuloside, and alizarin in the 
mengkudu fruit, as well as other anthraquinone compounds in the mengkudu root, are 
all proven antibacterial agents. These compounds have been shown to fight infectious 
bacteria strains such as Pseudomonas aeruginosa, Proteus morgaii, Staphylococcus 
aureus, Bacillus subtilis, Escherichia coli, Salmonella, and Shigela. These antibacterial 
elements within mengkudu are also responsible in the treatment of skin infections, 
colds, fevers, and other bacterial-related health problems (Wang at el., 2002). 
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Recently, one of study has demonstrated that scopoletin, a health promotor in 
mengkudu, inhibits the activity of E. coli, commonly associated with serious infections 
and even death. Mengkudu also helps in the treatment of stomach ulcer through its 
inhibition of the bacteria H. pylori (Duncan et al., 1998). Moreover, its anti-tubercular 
effects have also been reported in that a crude ethanol extract and hexane fraction 
from Morinda citrifolia showed antitubercular activity (Saludes et al., 2002).  
 
The antiviral activity of mengkudu was observed when a compound isolated 
from Mengkudu roots named 1-methoxy-2-formyl-3-hydroxyanthraquinone suppressed 
the cytopathic effect of HIV infected MT-4 cells, without inhibiting cell growth (Wang et 
al., 2002).  
 
Mengkudu’s antitumor activity study has also been reported. For instance, the 
alcohol-precipitate of mengkudu fruit juice (mengkudu-ppt) significantly prolonged the 
lifespan, by up to 75%, in C57 BI/6 mice implanted with Lewis lung carcinoma 
compared to that in the control group (Hirazumi et al., 1994). It can be concluded that 
the mengkudu-ppt seems to suppress tumor growth indirectly by stimulating the 
immune system (Hirazumi et al., 1996). Improved survival time and curative effects 
occurred when mengkudu-ppt was combined with suboptimal doses of the standard 
chemotherapeutic agents such as adriamycin (Adria), cisplatin (CDDP), 5-fluorouracil 
(5-FU), and vincristine (VCR), suggesting important clinical applications of mengkudu-
ppt as a supplementary agent in cancer treatment (Hirazumi & Furusawa, 1999). These 
results indicate that noni-ppt may enhance the therapeutic effects of anticancer drugs. 
Therefore it may be of benefit to cancer patients by enabling them to use lower doses 
of anticancer drugs to achieve the same or even better results. Recently, a study has 
reported the effects of over 500 extracts from tropical plants on the K-Ras-NRK cells. 
Damnacanthal, isolated from mengkudu roots, is an inhibitor of Ras function. The ras 
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oncogene is believed to be associated with the signal transduction in several human 
cancers such as lung, colon, pancreas, and leukemia (Wang et al., 2002). 
 
Two glycosides extracted from mengkudu-ppt have reportedly been effective in 
inhibiting cell transformation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) 
or epidermal growth factor (EGF) in the mouse epidermal JB6 cell line. The inhibition 
was found to be associated with the inhibitory effects of these compounds on AP-1 
activity (Liu et al., 2001; Sang et al., 2001).  
 
Mengkudu also possess anthelmintic ability.  An ethanol extract of the tender 
Noni leaves induced paralysis and death of the human parasitic nematode worm, 
Ascaris Lumbricoides, within a day (Raj, 1975).  
 
It has also been reported that the mengkudu fruits possesses analgesic and 
tranquilizing activities (Wang et al., 2002). In addition, a study tested the analgesic and 
sedative effects of extracts from the Morinda citrifolia plant. It was observed that the 
extract did “show a significant, dose-related, central analgesic activity in treated mice.” 
The study further stated that “these findings validate the traditional analgesic properties 
of this plant.” In fact, the analgesic efficacy of the mengkudu extract is 75 % as strong 
as morphine, yet non-addictive and side effect free (Younos et al., 1990).  
 
Apart from this, it has also been demonstrated that a total extract of the 
mengkudu roots has a hypotensive effect (Wang et al., 2002). A study into the anti-
inflammatory effect of mengkudu reported that the ethanol extract of mengkudu powder 
exhibited inhibition of COX-1 in in-vitro using aspirin and indomethacin as reference for 
COX-1 inhibitors. Additionally, it was observed that this inhibition of COX-1 by the 
ethanol extract of mengkudu was more potent than that in aspirin and indomethacin (Li 
et al., 2003).  
 18
The immunological activity of mengkudu has also been reported in that it was 
observed that an alcohol extract of mengkudu fruit at various concentrations inhibited 
the production of tumor necrosis factor-alpha (TNF-α), which is an endogenous tumor 
promoter (Hokama, 1993). Another study found that mengkudu-ppt contains a 
polysaccharide-rich substance that inhibited tumor growth. It did not exert significant 
cytotoxic effects in adapted cultures of lung cancer cells, but could activate peritoneal 
exudate cells to impart profound toxicity when co-cultured with tumor cells. This 
suggested the possibility that mengkudu-ppt may suppress tumor growth by activating 
the host immune system. Mengkudu-ppt was also capable of stimulating the release of 
several mediators from murine effector cells, including TNF-α, interleukin-1beta (IL-
β), IL-10, IL-12, interferon-gamma and nitric oxide (NO) (Hirazumi & Furusawa, 
1999).   
 
Mengkudu fruit has antioxidant; recently, a n-BuOH-soluble partition of the 
MeOH extract of Morinda citrifolia fruit has been reported that it has potent antioxidant 
property (Su et al., 2005).  
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 Table 1.2: Recently Reported Biological Effects of Morinda citrifolia 
(Rubiaceae)  
   
 
 
 
 
 
Biological Effects References 
Antibacterial activity   Wang at el., 2002 
A health promoter that inhibits the activity of E. coli; also helps 
in stomach ulcer treatment through inhibition of the H. pylori 
bacteria. 
Duncan  et al., 1998 
 Suppression of cytopathic effect of HIV infected MT-4 cells, 
without inhibiting cell growth. 
Wang at el., 2002 
Mycobacterium tuberculosis killer in  in vitro study Wang et al., 2002  
Anticancer activity  Hirazumi et al., 1994;  
Furusawa  et al., 2003 
Enhancement of the therapeutic effect of anticancer drugs such 
as Taxol. 
Wang at el., 2002 
Inhibition of the Ras (oncogene) function. Hiramatsu et al., 1993 
Inhibition tyrosine kinases activity Hiwasa  et al., 1999  
Inhibition of cell transformation in mouse epidermal JB6 cell 
line. 
Liu, et al., 2001;          
Sang et al., 2001 
Anathematic effect Raj, 1975;             
Fouraste et al., 2005    
Analgesic effect Li  et al., 2003     
Hypotensive effect Wang et al., 2002   
Antioxidant activity Kamiya  et al., 2004   
Antiangiogenic effect in human placental veins  Hornick et al., 2003  
Immunomodulation  Hirazumi  et al., 1996 
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1.8 Extrapolation of Animal Results to Man  
The pre-clinical safety evaluation of chemicals for use in man is usually done 
using mammalian species. Ideally, for a complete model animal species, the latter 
should be similar to man in four respects, namely (a) the rates and routes of 
metabolism, (b) the rates and routes of excretion, (c) the pharmacokinetic profile of 
which (a) and (b) are important determinants, and (d) the receptor response (Smith, 
1978).  
 
Species variations in drug metabolism can occur in respect to the speed at 
which metabolism occurs and in the metabolic pathways employed, and these 
differences arise mainly because of interspecies variations in enzyme control of phase I 
and phase II reactions (Smith, 1978).  
 
The projection of animal data directly to man should not be made on the 
assumption that the same dose of drug (in mg/kg) will attain the same concentration at 
the drug receptors in man as in animals (Brodie & Reid, 1971). In general, small 
animals such as mice metabolise foreign compounds at a faster rate than larger 
animals such as humans, consistent with differences in overall metabolic rates 
(Barrow, 2000). Rats are six times more efficient than man in handling xenobiotics 
based on its liver size/body weight (kg) which is twice that of man. Furthermore, 
concentrations of cytochrome P450 in rats is three times higher than in man. Besides 
that, ratio of dose relative to body weight (mg) to dose relative to body surface area 
(mg) showed that despite exhibiting similar drug effects on rats and man, dosage given 
to man is actually 10-times lower than that administered in rats (Klaassen & Doull, 
1980).      
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1.9 Objectives of Study   
This study is focused on the herbal products of Morinda citrifolia (Noni) which 
are most commonly found in supermarkets and its interaction with drugs based on 
phase I and phase II studies of metabolism using rat livers. Information about herbs is 
very limited because in most countries there are no universal regulatory systems that 
ensure the safety of phytopharmaceuticals. Yet uses of traditional medicine remain 
widespread in developing countries while the use of complementary and alternative 
medicine is increasing rapidly in developed countries in many parts of the world.  
The specific aims of this study were:  
 To study the in-vitro effect of the extract and two commercial products(Hawaiian 
and Tahiti) of mengkudu juice of Morinda citrifolia on liver aminopyrine metabolism 
by taking into account the effect of  internal factors such as disease (hypertension 
and diabetes), gender and age on liver aminopyrine metabolism.  
 To elucidate the molecular mechanism of the in-vitro effect of Morinda citrifolia 
preparations which significantly affect liver aminopyrine metabolism.  
 To study the ex-vivo effect of the mengkudu juice extract (MJE) of Morinda citrifolia 
on liver aminopyrine metabolism which yielded significant results during in-vitro 
studies.    
 To elucidate the molecular mechanisms of the ex-vivo effect of the Morinda citrifolia 
(MJE) at concentrations which significantly affect liver aminopyrine metabolism.  
 To study the ex-vivo effect of Morinda citrifolia (MJE) on phase II enzymes (GST 
and UDPGA) which yielded significant results during in-vitro studies in phase I.  
 To conduct a qualitatively chemical studies of MJE and two commercial products of 
Noni juice of Morinda citrifolia (Hawaiian and Tahiti) using UV/VIS, IR, 1HNMR 
spectrophotometers and HPTLC.   
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CHAPTER TWO   
EFFECT OF MORINDA CITRIFOLIA ON LIVER PHASE I AMINOPYRINE 
METABOLISM  
      
2.1  Introduction   
 
2.1.1  Phase I Drug Metabolism  
Main drug metabolism reactions associated with phase I liver metabolism are 
hydrolysis, reduction, hydration and oxidation. During the drugs phase I metabolism, 
new functional groups are introduced into the lipophilic drug structures. In phase I 
metabolism, oxidation can be further sub-classified into oxidation performed by 
microsomal mixed-function oxidase systems (cytochrome P450 dependent) and 
oxidation not cytochrome-dependent which has a number of enzymes in the body that 
are not related to the mixed-function oxidase systems. Most of these enzymes are 
primarily involved in endogenous compound metabolism which include alcohol 
dehydrogenase, aldehyde dehydrogenase, xanthine oxidases, amine oxidases, 
aromatases and alkylhydrazine. Complete mixed-function oxidase system which 
includes cytochrome P450, NADPH-cytochrome P450 reductase has the following 
types of oxidation metabolism namely : aromatic hydroxylation, S-oxidation, 
phosphothionate oxidation, aliphatic hydroxylation epoxidation, oxidative deamination, 
N-oxidation, dehalogenation and dealkylation (Gibson & Skett, 1994).  
 
The present study involved dealkylation reaction, in particular, N-demethylation 
which is responsible for the metabolism of aminopyrine drug model.  
    
2.1.1.1  Cytochrome P450s and Their Role on Drug Metabolism   
The Cytochrome P-450 (CYP450) system is a family of heme based enzymes 
located in the smooth endoplasmic reticulum, particularly concentrated in hepatocytes 
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and mucosal enterocytes but also found in the kidneys, skin and lung tissues of 
humans (Gibson & Skett, 1994; Clarke & Jones, 2002). Known also as the mixed 
function oxidases, it is one of the most important systems in the biotransformation of 
drugs. The CYP450 families of enzymes are responsible for phase I xenobiotic 
metabolism, catalyzing predominantly oxidation, reduction and hydrolysis reactions 
which render lipophilic compounds more polar, prior to the phase II processes of thiol 
conjugation, glucuronidation, sulfation or acetylation which enable the metabolites to be 
excreted by the kidneys or liver. A microsomal superfamily of isoenzymes transfer 
electrons and thereby catalyzes the oxidation of many drugs. The electrons are 
supplied by NADPH-cytochrome P-450 reductase, a flavoprotein that transfers 
electrons from NADPH (the reduced form of nicotinamide-adenine dinucleotide 
phosphate) to cytochrome P-450 (Gibson & Skett, 1994). Cytochrome P-450 enzymes 
are grouped into 14 mammalian gene families that share sequence identity and 17 
subfamilies. They are designated by a root symbol CYP, followed by an Arabic number 
for family, a letter for subfamily, and another Arabic number for the specific gene 
(Clarke & Jones, 2002). Enzymes in the 1A, 2B, 2C, 2D, and 3A subfamilies are the 
most important in mammalian metabolism; in human 35 P450 enzymes were described 
although only 18 P450 enzymes in families 1, 2, and, 3 appear to be responsible for the 
metabolism of drugs and therefore are potential sites for drug interactions. It has been 
noted that   CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are important in 
drug metabolism (Clarke & Jones, 2002). The specificity of these enzymes helps 
explain many drug interactions. P450 enzymes are found throughout the body, 
however, the liver and the intestinal epithelia are the predominant sites for P450-
mediated drug interactions and they are also the sites worth considering in most detail 
with respect to drug interactions.  
 
 Many different P450 enzymes have been detected in the intestine from various 
species, including man (Yamamoto et al., 1998; Zhang et al., 1998; Hiroi et al., 1998; 
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Zeldin et al., 1997; Prueksaritanont et al., 1996; Kaminsky & Fasco, 1991). However, 
the CYP3A4 is overwhelmingly the most significant P450 enzyme in the human 
intestine (Lown et al., 1994; Kolars et al., 1994). The fact that CYP3A4 is the P450 
enzyme of significant concern for drug to drug interactions in the intestine is supported 
by a number of pharmacokinetic studies. Intestinal pre-systemic elimination has been 
shown for several drugs metabolized by CYP3A4. e.g. cyclosporine (Wu et al., 1995), 
tacrolimus (Hashimoto et al., 1998; Lampen et al., 1995) sirolimus (Lampen et al., 
1998) midazolam (Paine et al., 1996), saquinavir (Wacher et al., 1998), felodipine 
(Wang et al., 1989; Lown et al., 1997), and nefazadone (Marathe et al., 1995). 
Grapefruit juice has been shown to have significant interaction with a number of these 
drugs (Ameer & Weintraub, 1997), because grapefruit affects the activity of CYP3A4 in 
the intestine (Lown et al., 1997; Fuhr, 1998; Feldman, 1997).  
 
In the human liver, the relative content of the major P450 enzymes has been 
determined in several studies and a general consensus has emerged. On average, 
CYP3A4 is quantitatively the most important in the body, while with CYP2C8, CYP2C9, 
CYP2A6, CYP2E1, and CYP1A2 present in somewhat lower quantities, on the other 
hand CYP2C19 and CYP2D6 are of relatively minor quantitative importance (Clarke & 
Jones, 2002). CYP3A4 is responsible for approximately 50% of the P450-mediated 
metabolism of marketed pharmaceuticals. Nevertheless, CYP2D6 has a 
disproportionate share, (~25%) of the overall total of enzymes, in comparison to the 
amount of other enzymes present in the liver.  
 
2.1.1.2 Aminopyrine   
Aminopyrine was introduced into medicine in the late nineteenth century as 
an antipyretic, and subsequently was also widely used as an analgesic and 
antiinflammatory agent. However, clinical use of aminopyrine was sharply curtailed 
after its potentially fatal bone marrow toxicity, agranulocytosis, was recognized. 
